دورية أكاديمية
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
| العنوان: | Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. |
|---|---|
| المؤلفون: | Ryan DH; Pennington Biomedical Research Center, Baton Rouge, LA, USA. ryandh@pbrc.edu., Lingvay I; Department of Internal Medicine/Endocrinology and Peter O' Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA., Deanfield J; Institute of Cardiovascular Science, University College London, London, UK., Kahn SE; VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA., Barros E; Novo Nordisk A/S, Søborg, Denmark., Burguera B; Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA., Colhoun HM; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Cercato C; Obesity Unit, Department of Endocrinology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil., Dicker D; Internal Medicine Department D, Hasharon Hospital-Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Horn DB; Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston, TX, USA., Hovingh GK; Novo Nordisk A/S, Søborg, Denmark., Jeppesen OK; Novo Nordisk A/S, Søborg, Denmark., Kokkinos A; First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA., Meyhöfer SM; Institute of Endocrinology & Diabetes, University of Lübeck, Lübeck, Germany., Oral TK; Novo Nordisk A/S, Søborg, Denmark., Plutzky J; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., van Beek AP; University of Groningen, University Medical Center Groningen, Department of Endocrinology, Groningen, the Netherlands., Wilding JPH; Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK., Kushner RF; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. |
| المصدر: | Nature medicine [Nat Med] 2024 Jul; Vol. 30 (7), pp. 2049-2057. Date of Electronic Publication: 2024 May 13. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Nature Publishing Company Original Publication: New York, NY : Nature Pub. Co., [1995- |
| مواضيع طبية MeSH: | Glucagon-Like Peptides*/therapeutic use , Glucagon-Like Peptides*/adverse effects , Weight Loss*/drug effects , Obesity*/drug therapy , Obesity*/complications , Body Mass Index*, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Treatment Outcome ; Double-Blind Method ; Cardiovascular Diseases/prevention & control |
| مستخلص: | In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m - 2 ) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years. ClinicalTrials.gov identifier: NCT03574597 . (© 2024. The Author(s).) |
| References: | Curr Obes Rep. 2017 Jun;6(2):187-194. (PMID: 28455679) Circulation. 2011 Nov 1;124(18):1996-2019. (PMID: 21947291) Nat Rev Endocrinol. 2020 Mar;16(3):177-189. (PMID: 32020062) Nutr Res Rev. 2010 Dec;23(2):247-69. (PMID: 20819243) Endocr Pract. 2016 Jul;22 Suppl 3:1-203. (PMID: 27219496) Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. (PMID: 28110911) Diabetes Care. 2011 Oct;34(10):2152-7. (PMID: 21836103) Circulation. 2023 Nov 14;148(20):1606-1635. (PMID: 37807924) N Engl J Med. 2021 Mar 18;384(11):989-1002. (PMID: 33567185) Circulation. 2006 Feb 14;113(6):898-918. (PMID: 16380542) Nat Rev Drug Discov. 2022 Mar;21(3):201-223. (PMID: 34815532) N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186) N Engl J Med. 2023 Dec 14;389(24):2221-2232. (PMID: 37952131) N Engl J Med. 2017 Jul 6;377(1):13-27. (PMID: 28604169) Obesity (Silver Spring). 2023 Jan;31(1):111-122. (PMID: 36502289) Am Psychol. 2020 Feb-Mar;75(2):235-251. (PMID: 32052997) Int J Epidemiol. 2006 Feb;35(1):83-92. (PMID: 16339600) Lancet Diabetes Endocrinol. 2023 Jan;11(1):58-62. (PMID: 36460014) J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023. (PMID: 24239920) Diabetes Care. 2011 Jul;34(7):1481-6. (PMID: 21593294) PLoS Med. 2020 Jul 28;17(7):e1003198. (PMID: 32722671) Dis Model Mech. 2011 Nov;4(6):733-45. (PMID: 22065844) Am Heart J. 2020 Nov;229:61-69. (PMID: 32916609) |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03574597 |
| المشرفين على المادة: | 53AXN4NNHX (semaglutide) 62340-29-8 (Glucagon-Like Peptides) |
| تواريخ الأحداث: | Date Created: 20240513 Date Completed: 20240719 Latest Revision: 20240727 |
| رمز التحديث: | 20240727 |
| مُعرف محوري في PubMed: | PMC11271387 |
| DOI: | 10.1038/s41591-024-02996-7 |
| PMID: | 38740993 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1546-170X |
|---|---|
| DOI: | 10.1038/s41591-024-02996-7 |